Rick Simpson Oil (RSO) in Butler County, Kansas: The Complete Guide by OilWell Cannabis

If you’re reading this in El Dorado, Andover, Augusta, or anywhere across Butler County’s 1,430 square miles of Kansas prairie, you’re likely searching for answers that conventional medicine hasn’t fully provided. Maybe it’s for the chronic back pain that makes walking the fields near El Dorado Lake impossible. Maybe it’s supporting a loved one through chemotherapy at Susan B. Allen Memorial Hospital. Maybe you’re a veteran from McConnell Air Force Base wrestling with PTSD after tours overseas. Or perhaps you’re one of the many Butler County residents who’ve watched the opioid crisis devastate rural Kansas and you’re desperate for alternatives that don’t come with a prescription pad.

We get it. OilWell Cannabis was built from the same desperation, the same refusal to accept “there’s nothing more we can do.” Our founder Colin Valencia faced a choice no pet owner should ever have to make when his dog Bentley was paralyzed and facing euthanasia. That same choice echoes through countless Butler County homes every year when the vet bill is too high, when the cancer treatment costs too much, when the pain medication stops working.

This guide isn’t here to sell you hope. It’s here to give you everything we’ve learned about Rick Simpson Oil—its history, its science, its evolution, and most importantly, how our modern formulation might fit into your life here in south-central Kansas. We’ll be blunt: Kansas has some of the most restrictive cannabis laws in America. But the 2018 Farm Bill created a legal pathway that makes our THCa-rich RSO accessible in Butler County, across Kansas, and internationally. We’re not asking you to trust us because we’re from Houston—we’re asking you to evaluate the evidence, understand the chemistry, and decide for yourself if this legal alternative deserves a fair shot in your health journey.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical researcher—he was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began not with laboratory research but with personal suffering and a deep distrust of the medical system that failed him. In many ways, his story mirrors what we hear from patients across Butler County: people who’ve been let down by institutions, who’ve cycled through ineffective prescriptions, who’ve been told their pain is “all in their head” or that there are “no more options.”

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. According to Simpson, the medications prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused .

Simpson’s interest deepened after learning about a 1974 NIH-funded study at the Medical College of Virginia, where THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point for Simpson, even though its findings were never replicated in controlled human cancer trials .

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification, biopsy confirmation, or clinical follow-up has been published in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil .

Important context: Simpson’s account is presented here as his personal testimony, not medical evidence. The absence of clinical documentation means these events cannot be evaluated as scientific proof, but they are historically significant as the catalyst for a global movement.

The crusade — spreading the oil

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community, charging nothing. By his account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more .

His story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials, and framed his work as a grassroots challenge to pharmaceutical interests. It was distributed freely online and became foundational within cannabis communities—for many, it was their introduction to concentrated cannabis oil as medicine .

Simpson’s advocacy brought him into direct conflict with Canadian law. The RCMP raided his property in 2005 and 2009, seizing plants and equipment. He was charged with cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada for Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad .

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, detailing his experience, oil-making process, and philosophical views .

Throughout his public career, Simpson maintained that cannabis oil—particularly high-THC oil made by his method—could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge .

Important context: Simpson’s conspiratorial framing reflects a worldview shared by many in the early cannabis movement. It’s relevant to understanding RSO’s cultural significance, but it doesn’t validate his medical claims.

The traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core recommendation was consuming 60 grams of concentrated cannabis oil over approximately 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions .

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over roughly 90 days. Simpson considered this the minimum necessary for serious cancer treatment.

Titration schedule

• Week 1: Begin with a dose the size of half a grain of rice—about 10-15mg of oil—taken three times daily. Total daily intake: ~30-45mg.
• Weeks 2-5: Double the dose every four days to build THC tolerance gradually. By week 5, reach ~1 gram (1,000mg) per day, divided into three doses of ~333mg each.
• Weeks 5-12: Maintain 1 gram per day until all 60 grams are consumed.

Administration methods

• Primary — oral: Place dose under tongue (sublingual) or swallow. Simpson considered oral ingestion essential for systemic absorption.
• Secondary — topical: Apply directly to skin cancers/lesions, cover with bandage, change every 3-4 days. Combine with oral dosing for skin cancers.
• Not recommended — inhalation: Simpson didn’t recommend smoking or vaporizing as primary treatment, though he acknowledged it for immediate symptom relief.

Tolerance and psychoactive effects

Simpson claimed patients develop significant THC tolerance within 3-4 weeks. He considered euphoria, sedation, or disorientation temporary side effects and urged patients not to let the high discourage them. He recommended initial doses at night to sleep through early psychoactive effects and warned against driving during titration.

Post-protocol maintenance

After completing 60 grams, Simpson recommended 1-2 grams of oil per month indefinitely for long-term health and cancer prevention.

Dietary and lifestyle recommendations

Simpson also advocated reducing sugar, avoiding processed foods, and improving overall nutrition, though this was secondary to the oil protocol.

Important context for evaluating this protocol

This protocol was designed by one person based on personal experience. Several critical points apply:

• No controlled trial validation. No published randomized controlled trials, cohort studies, or well-documented case series evaluate this specific 60-gram/90-day protocol for any cancer type or condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes single-strain, THC-dominant extract with no standardized potency. Actual THC content varied widely.
• Very high THC exposure. At peak dosing, patients consumed ~1 gram of high-THC oil daily. Assuming 60-90% THC, this translates to 600-900mg of delta-9 THC per day—far exceeding anything studied clinically. For context, FDA-approved dronabinol is typically dosed at 2.5-20mg per day.
• Real risks at these doses. Consuming 600-900mg of THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].
• Oncology context. Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as primary treatment—potentially in place of proven therapies—introduces harm beyond the oil itself.

What is traditional Rick Simpson Oil — the product

Traditional RSO refers to the specific oil Simpson made, defined by his method and materials, not lab specifications.

Source material

Simpson used high-THC, indica-dominant cannabis strains. He favored heavy, sedating indica genetics and generally recommended against sativa for cancer treatment. He grew his own cannabis or sourced from trusted growers. There was no strain standardization—starting material varied by availability and season.

Extraction solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid. He later endorsed 99% isopropyl alcohol as an alternative. Neither is food-grade, which raises significant safety concerns.

Extraction process

1. Dry cannabis placed in bucket
2. Covered with solvent and agitated to dissolve cannabinoids
3. Solvent poured through filter into collection vessel
4. Process repeated with fresh solvent
5. Combined solvent washes placed in rice cooker
6. Solvent evaporated at low heat (sufficient to decarboxylate THCa and destroy terpenes)
7. Thick, dark oil remained
8. Final oil transferred to oral syringes

Appearance and physical characteristics

Traditional RSO was nearly black, thick, tar-like, sticky, difficult to handle at room temperature, with strong cannabis odor and possible solvent-residual smell.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC: Heat converted essentially all THCa to delta-9 THC.
• Naturally occurring minor cannabinoids: Whatever CBD, CBN, CBC, CBG the source strain contained were present at natural ratios, but not controlled, measured, or targeted.
• No ratio control: Profile entirely determined by genetics and growing conditions.
• Estimated THC content: Likely 60-90% total THC by weight, though never lab-verified traditionally.

Terpene content

Minimal to none. Solvent extraction and high-heat evaporation stripped terpenes. Traditional RSO was effectively a cannabinoid-only product.

Standardization and testing

None. Every batch was different depending on plant material, growing conditions, solvent purity, extraction technique, evaporation temperature/duration, and maker’s process. No Certificate of Analysis, cannabinoid quantification, or contaminant screening.

Residual solvent risk

This is one of the most significant safety concerns. Naphtha and isopropyl alcohol are not food-grade. Naphtha may contain benzene, toluene, and other toxic/carcinogenic compounds. Incomplete purging—difficult to verify without lab testing—leaves potentially harmful residues.

Modern extraction uses food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s claims vs. the evidence record

Simpson stated that RSO could cure cancer and was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, MS, and more. He was adamant and consistent throughout his advocacy career .

What Simpson was not

He was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted results to peer review. His evidence base consisted entirely of personal experience, self-reported patient outcomes, and informal testimonials—with no controls, independent verification, imaging confirmation, long-term follow-up, or blinding.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature exists and is scientifically interesting:

• In vitro studies show THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines .
• Animal models show some tumor-growth inhibition in mice and rats treated with cannabinoids .
• These findings generate legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro/animal results and human clinical outcomes is vast.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been exploratory, small, and have not produced results supporting cancer-cure claims .

Institutional positions

• U.S. National Cancer Institute (NCI): Acknowledges cannabinoids have been studied for potential anticancer effects in lab and animal models but does not endorse cannabis or cannabis oil as cancer treatment .
• U.S. Food and Drug Administration (FDA): Has not approved any cannabis plant product for cancer treatment. Only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting [1].
• Health Canada: Has never approved RSO or cannabis oil as cancer cure.
• NCCIH: States strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea/vomiting, and appetite-related indications in HIV/AIDS—not cancer cure [1].

What Simpson got right

Simpson drew attention to cannabinoids as serious biomedical research when the world was ignoring it. His advocacy helped create political, cultural, and social conditions for the legal cannabis industry and cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and “RSO” remains the most recognized name for full-spectrum cannabis extract.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it’s not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative-medicine literature.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly and loosely across the legal cannabis industry. Many products labeled RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic .

Simpson himself has been critical of commercial products using the RSO name while departing from his original method and philosophy. He gave his oil away for free and urged others to make their own rather than buy from companies .

This philosophical tension is worth acknowledging. Simpson believed in DIY, free-access model where anyone could grow cannabis, extract oil, and treat themselves without corporate or governmental intermediaries. The modern cannabis industry has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents improvement (quality control, lab testing, dosing precision) or betrayal (profit extraction, regulatory gatekeeping) depends on perspective, and the cannabis community remains divided.

What is not disputed is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this document.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab testing	Not available or performed	Full panel testing (potency, terpenes, pesticides, heavy metals, residual solvents, microbial)
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

Our formulations are not traditional RSO. They are informed by the tradition but depart deliberately and evidence-motivatedly:

Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. Our formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. We include live terpenes at 5% with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing [20][21][23][24][25][26][27][28][29].

THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity lost when THCa converts to THC [12].

Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC—often 60-90% of total cannabinoid content. Our sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than single-compound dominance.

Product format innovation. Simpson envisioned only one format: oral oil administered from a syringe. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, and other toxic/carcinogenic compounds. Incomplete purging—difficult to verify without analytical chemistry equipment—leaves potentially harmful residues.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods like headspace gas chromatography. This is one of the most straightforward improvements the modern regulated cannabis industry has made over traditional RSO production.

This evolution connects directly to the product-quality discussion in our General Knowledge section, which emphasizes that product quality matters as much as molecule identity and that labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products [1][10][11][14].

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker—typically sustained at or near the solvent’s boiling point (60-80°C for naphtha, ~82°C for isopropyl alcohol)—was sufficient to convert essentially all THCa into delta-9 THC. This meant acidic cannabinoids abundant in raw cannabis were lost as distinct compounds.

Our sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile in our General Knowledge section, which notes that THCa itself does not produce psychoactive effects associated with THC but that interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time [12].

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin volatilizing between 21-157°C, with many abundant terpenes—including myrcene, limonene, and pinene—boiling below 180°C. Traditional RSO production destroyed terpenes two ways: dissolving them into solvent wash with cannabinoids, then evaporating them off during high-heat solvent removal.

This meant traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

Our formulas specify live terpenes at 5% with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each terpene has its own evidence profile in our General Knowledge section. The entourage-effect literature [20][29] provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and most of the world. There was no regulatory framework, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing—it’s a description of the environment.

This document takes a fundamentally different approach. Our General Knowledge section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor RSO’s historical origin while committing to modern cannabinoid science standards. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison between his dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Key differences:

• Cannabinoid concentration. Our sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was ~60-90% delta-9 THC. Our formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg)—a completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. Our formula includes live terpenes at 5%, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak delivered ~600-900 mg of delta-9 THC per day. Our sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for our products should be developed independently of Simpson’s protocol, informed by per-compound evidence in our General Knowledge section and responsible titration principles accounting for each cannabinoid’s safety profile.

References for this section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas—a city that, like Wichita just 150 miles north of Butler County, understands what it means to build something from grit and determination. Colin grew up in McAllen, Texas, right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border—much like how parts of rural Kansas have been hollowed out by economic shifts, though here it’s the loss of manufacturing and agricultural consolidation rather than cartel violence.

McAllen is a city of contrasts—vibrant culture and thriving retail, yet deeply affected by poverty and limited opportunities outside retail and healthcare. Reynosa is an industrial hub plagued by violence and cartel activity. Colin’s childhood in this environment taught him to hustle early, taking on risky work transporting items across the border for various groups. Those experiences exposed him to complexities and dangers that echo what many Butler County residents know from different contexts—whether it’s the dangers of agricultural work, the risks of oil field jobs, or the economic precarity of small-town life.

A lot of Colin’s best friends have been killed or are in prison because of associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, he had to leave home for good—much like how many young people leave Butler County for opportunities elsewhere, though usually not under such dire circumstances.

Despite the dangers, Colin didn’t fall into the darkest paths available, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines OilWell’s approach, much like how Butler County’s best farmers combine generations of plant knowledge with modern agricultural technology.

Bentley’s story—the foundation

The company’s origin story begins with a dog named Bentley. Bentley was more than a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley wasn’t an option. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything: “You’ve moved how many tons of weed and you’ve never heard of CBD?” asked a rescue worker named Jessica.

Colin had cannabis experience—but it was recreational. Jessica’s question exposed a blind spot that became a mission. Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration, dementia, glaucoma, and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into cannabis beyond just getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people. Bentley’s story is OilWell Cannabis’s foundation, driving our commitment to quality, innovation, and compassionate care.

From personal struggle to professional purpose

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat notoriously difficult and dangerous—using the cannabinoid knowledge he developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. Colin personally uses the vape form to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13: Houston’s cannabis authority documents our journey

Between September 2019 and April 2023, ABC13 Houston—serving America’s fourth-largest city—featured Colin and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or breadth.

When ABC13 needed to explain a new cannabis product, it called Colin. When a state agency reversed Delta-8 legality overnight, it called Colin. When a sitting president announced marijuana pardons and needed someone who had personally lived with a cannabis conviction to provide context, it called Colin. When the station wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and voice that anchored the report.

These seven features document a consistent pattern of credibility that transcends geography. For Butler County readers, this mainstream media validation from a major-market ABC affiliate establishes authority that no amount of marketing can replicate. While Kansas media may not have covered cannabis as extensively, OilWell has the sustained media relationship most cannabis companies never achieve.

September 15, 2019 — The foundational philosophy

“I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This 2019 quote is the seed of everything OilWell would become. The open-source formula publication, the evidence-based research documentation, the refusal to make unsupported claims—it all traces here.

March 22, 2021 — Pain comes in many forms

“People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

This quote resonates deeply in Butler County, where pain manifests as chronic back pain from decades of agricultural labor, as arthritis from working the land, as cancer pain, as PTSD from military service, as grief from the opioid crisis claiming lives in communities like El Dorado and Augusta.

May 24, 2021 — Radical honesty

“I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

This exchange with Steve Campion became one of Colin’s most iconic media moments—radical honesty on mainstream television. For Butler County’s conservative audience, this unfiltered truth-telling builds trust more than polished marketing ever could.

August 20, 2021 — Community health in action

OilWell gave away approximately $35,000 in product (1,000 caviar pre-rolls) to encourage COVID-19 vaccination. The company coordinated with the city of Houston, hosted the giveaway at HydroShack Hydroponics, and did it with no political strings attached. This documented action demonstrates community-first philosophy that Butler County residents—who value neighbors helping neighbors—can respect.

October 19, 2021 — Ethical leadership during crisis

When Texas DSHS classified Delta-8 as Schedule I overnight, Colin proactively removed all Delta-8 products before enforcement began and tried to spread the word to other operators unknowingly shipping Schedule I narcotics. He absorbed a major revenue loss to act ethically. This is the kind of leadership Butler County’s agricultural community understands—doing the right thing even when it costs you.

October 7, 2022 — Personal stakes revealed

The feature opened with OilWell’s CBD vending machine innovation, then revealed Colin has previously faced charges for marijuana possession. This transforms the entire media record—every quote about therapy, education, not selling snake oil carries additional weight when you understand the person saying it has personally experienced cannabis criminalization. For Butler County residents who’ve seen friends or family face cannabis charges, this creates immediate authenticity.

April 21, 2023 — The Renaissance framing

“Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

As Kansas debates its own cannabis future—with neighboring Oklahoma having medical cannabis and Colorado having recreational—this perspective reframes the present as opportunity rather than waiting. The comparison of Texas’s 10,000 active medical cannabis patients versus Florida’s 700,000 (with two-thirds the population) demonstrates untapped demand relevant to Kansas policy discussions.

Current operations: A real business, not a fly-by-night operation

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). We’ve been operating since 2019, generate approximately one million dollars in annual revenue, maintain a near-5.0 Google rating, and are Texas DSHS licensed. Our products are not mass-produced—they’re carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only our own recipes and ideas.

For Butler County residents, these operational details establish that OilWell is a real, successful, licensed business—not an anonymous online brand that might disappear tomorrow. When you’re dealing with health issues, you need a company with staying power, not a pop-up operation.

The OilWell RSO philosophy: Four core principles

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in deliberate, evidence-motivated ways designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define our approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; we engineered a product that puts that control in your hands through chemistry rather than rhetoric.

3. Open-source formulas. We publish our complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; we adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.

4. Evidence-informed, not evidence-overstating. Our General Knowledge section represents our commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill compliance and the THCa legal framework in Kansas

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of OilWell’s RSO product design.

Kansas-specific context: Kansas has NO medical or recreational cannabis program. The state has been hostile to cannabis, with some of the most restrictive policies in America. However, the Farm Bill’s federal supremacy means that hemp-derived products meeting the <0.3% delta-9 THC threshold are legal to purchase, possess, and use in Kansas. This is the legal pathway that makes our RSO accessible to Butler County residents without a medical card.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3% threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in Kansas.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at point of sale because it has not been converted to delta-9 THC.

The practical significance is substantial. You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

This means the same product can function as non-psychoactive anti-inflammatory (used raw) or full-potency psychoactive cannabinoid product (after home decarboxylation). You control the decision. The product is legal everywhere all component cannabinoids are legal, which enables us to ship to Kansas and other jurisdictions where hemp-derived products with less than 0.3% delta-9 THC are permitted.

Important legal notice for Kansas residents: THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with Kansas laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, and receipts. While the product is legal at point of sale, decarboxylation creates delta-9 THC, which remains a controlled substance under Kansas law if it exceeds 0.3% in the final product. Kansas law enforcement may interpret this differently than federal law. We provide this information for educational purposes; consult legal counsel if needed.

Open-source formulas—why OilWell publishes everything

OilWell publishes our complete RSO formulas—every cannabinoid, every milligram amount, every percentage—in public documents including this one. Our RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this guide.

The rationale is straightforward: if someone cannot afford our products—$129.99 for the sublingual oil, $49.99 for the vape cartridge—they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. The formulas in our product sections are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

As Colin said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The decarboxylation choice—patient-controlled potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving patients with no choice about psychoactivity—the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1 — Raw, no heat. All 1,500 milligrams stays as THCa—completely non-psychoactive. The THCa evidence profile in our General Knowledge section describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving through the Flint Hills, tending cattle, operating machinery on your Butler County property—zero psychoactive impairment.

Option 2 — Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45-60 minutes converts 1,500 milligrams of THCa into ~1,315 milligrams of delta-9 THC. Combined with existing 90 milligrams, this yields ~1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO—100% legally, because decarboxylation occurs at your discretion after purchase. You may also transfer a controlled portion to a second oven-safe container, decarboxylating only what you intend to use and preserving the remainder raw.

Option 3 — Vape, auto-decarboxylation. Our RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting loss of a CO₂ molecule.

This design puts the potency decision entirely in your hands—aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing it through actual product chemistry rather than a one-size-fits-all approach.

Solvent-free production

OilWell’s RSO is not a traditional extraction product. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile—a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website.

For Butler County residents who’ve heard stories about contaminated cannabis products or who value the agricultural purity that defines our farming communities, this testing approach provides the transparency and safety assurance you deserve.

The broader OilWell product portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach — OilWell’s most popular product. Asshole Peach is a carefully formulated experience providing euphoric, long-lasting sensation, particularly favored by veterans for relieving pain and PTSD symptoms without being overly aggressive. For Butler County’s significant veteran community—whether from McConnell AFB, Fort Riley, or earlier service—this product lineage speaks directly to shared experiences.

Peace Gummies — Developed directly from Colin’s own PTSD and benzodiazepine addiction experience. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in vape form for quick relief—Colin personally uses the vape to manage his insomnia and severe PTSD. For Butler County residents dealing with the fallout of the opioid crisis or struggling with pharmaceutical dependence, this product represents lived experience turned into solution.

Custom creations — OilWell offers custom-made products tailored to specific needs. Whether specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, we design targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary needs—important in Butler County where diabetes rates reflect national rural health challenges.

Two product formats

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19% (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35% (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

Complete RSO Guide — Our full product guide with science, competitive analysis, protocols, and ordering information is available on our website.

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset—crucial for breakthrough symptoms
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration—covers overnight or workday
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required—fits in pocket for Flint Hills ranch work
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments—important for titration
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment—safe for operating equipment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for full therapeutic effect

Competitive comparison—OilWell RSO vs. alternatives

OilWell RSO vs. Texas dispensary RSO (e.g., Texas Original)

Dimension	Texas dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (~420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No—always fully psychoactive	Yes—THCa non-psychoactive until you heat it
Access requirements	Medical card with qualifying condition	Age 21+ only, no medical card required
Delivery	Must travel to physical dispensary	Ships directly to Butler County, Kansas
Farm Bill compliant	No—state medical cannabis program	Yes—less than 0.3% delta-9 THC

OilWell RSO vs. hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	~950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to ~1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes—via THCa decarboxylation and delta-8 THC
Approximate price	$40-$50	$129.99

For Butler County residents who may have tried basic CBD products from local stores or online, the comparison is stark: OilWell delivers 16.5 times more total cannabinoids, includes six additional cannabinoids beyond CBD, offers a psychoactive pathway, and ships directly to your door without requiring a medical card.

Condition-specific usage context for Butler County residents

Important disclaimer: These usage contexts are informed by cannabinoid research cited in our General Knowledge section and our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not substitutes for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids. For Butler County residents, this means being especially cautious during harvest season, hunting trips, or any work requiring heavy machinery.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment at Susan B. Allen Memorial Hospital or your Wichita oncology center
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea/vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic pain (fibromyalgia, arthritis, neuropathy from agricultural work or oil field injuries)

• Daytime: 0.3-0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment, safe for operating tractors, combines, or oil equipment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset during flare-ups
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep support (common issue in rural communities with shift work and stress)

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage investigated in 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance
• Evidence context: CBN sleep evidence [16][17]

Anxiety and stress (whether from economic pressures, family responsibilities, or PTSD)

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

General titration principle for Butler County residents: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors. This is especially important for Kansas residents who may have lower cannabis tolerance due to limited exposure.

Delivery and global accessibility to Butler County, Kansas

OilWell ships nationwide to all 50 states where Farm Bill-compliant products are legal, including Kansas. We ship directly to Butler County via USPS Priority Mail (2-3 business days), FedEx, and UPS Ground (3-5 business days).

For Butler County residents:

• Discreet packaging: No cannabis branding visible on exterior—important in communities where package privacy matters
• Tracking provided: Know exactly when your order arrives at your El Dorado, Andover, Augusta, or rural route address
• Temperature-stable packaging: Ensures product integrity during Kansas summers when mailboxes can exceed 100°F
• Signature-required option available: For those concerned about package security

International shipping: While Kansas residents won’t need this, it’s worth noting that OilWell ships internationally to jurisdictions with compatible hemp laws. This global accessibility completes a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime.

OilWell’s PANDEM1C SEO technology—a proprietary system with 14 million distinct geopolitical locations in its database and over 300 AI models—drives organic search visibility across six continents, making OilWell products discoverable to patients worldwide.

For Butler County specifically: when you search “RSO Kansas,” “Rick Simpson Oil Butler County,” “legal cannabis oil El Dorado,” or similar terms, our educational content and product information are optimized to reach you with accurate, science-based information rather than hype.

How the OilWell formulas connect to the evidence in this document

Every cannabinoid in OilWell’s formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in our General Knowledge section. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

The formulas we publish are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to current evidence. Where our RSO guide makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context—the same peer-reviewed citations, the same evidence-tier assessments, the same cautious interpretation framework.

Our evidence hierarchy, overstatement warnings, and safety notes apply equally to our own products. This document does not exempt OilWell from the same evidence standards applied to the broader cannabinoid field. That is intentional. Our position—stated by Colin Valencia in 2019—is that people deserve the best possible version of information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

OilWell Cannabis is more than a brand—it is a promise to customers that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. And as we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that defined us from the day Bentley got up, walked across the room, and brought his ball to play.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia—Houston’s go-to cannabis authority, relevant to Kansas

Between September 2019 and April 2023, ABC13 Houston featured Colin Valencia and OilWell Cannabis in seven distinct news segments. Five different reporters sought Colin out across those years. No other Houston cannabis operator appears with that frequency or breadth.

These features document a consistent pattern. When ABC13 needed to explain a new cannabis product, it called Colin. When a state agency reversed Delta-8 legality overnight, it called Colin. When a sitting president announced marijuana pardons, it called Colin.

For Butler County residents evaluating a company from another state, this mainstream media validation from a major-market ABC affiliate establishes credibility that transcends geography. Kansas may not have equivalent cannabis media coverage, but you can verify OilWell’s media record yourself through ABC13’s archives.

Complete chronology of ABC13 features

September 15, 2019 — Texas CBD businesses booming
Colin’s foundational quote: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try…”

March 22, 2021 — Direct-to-consumer before decriminalization
Colin as ecosystem builder helping other entrepreneurs. His therapy quote: “Pain comes in a lot of different forms.”

May 24, 2021 — Delta-8 THC “legal weed” investigation
Iconic exchange: “Maybe you want to get high.” Colin’s radical honesty balanced with medical caution and regulatory advocacy.

August 20, 2021 — COVID vaccine giveaway
OilWell donated ~$35,000 in product (1,000 caviar pre-rolls) to encourage vaccination, coordinating with Houston city government—documented community action with no political strings.

October 19, 2021 — Delta-8 ban impact
Colin proactively removed all Delta-8 products before enforcement and warned other operators—a defining moment of ethical leadership during regulatory crisis.

October 7, 2022 — Biden marijuana pardon
Revealed Colin’s personal marijuana conviction history, transforming every prior quote with additional weight and authenticity.

April 21, 2023 — 4/20 industry Renaissance
Colin framed the present as opportunity: “Right now is actually a pretty – like Renaissance – pretty important time…”

The through-line—what the media record reveals

Consistency across years. Through every legal shift, ABC13 returned to Colin as a primary source.

Breadth of expertise. Features span business, consumer health, product investigation, legal analysis, political commentary, and community advocacy.

Community action. The COVID giveaway and Delta-8 proactive removal demonstrate community-first philosophy.

Personal stakes. Colin’s conviction history makes his media presence more powerful—he’s lived the consequences.

Evolution of language. From “local wholesaler” in 2019 to industry authority in 2023, the media record tracks authentic growth.

These features are not marketing materials. They are independently produced, editorially controlled news segments that repeatedly identified Colin Valencia as the most credible voice in Houston’s legal cannabis industry. That is recognition that cannot be purchased—it can only be earned.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then mechanistic/preclinical literature when human data are sparse. This weighting matters because the evidence base is not evenly distributed. Of compounds listed, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes depend more on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

For Butler County residents with science-literate backgrounds—perhaps connected to the aviation industry, agriculture research, or healthcare—this methodology transparency demonstrates why OilWell’s content is more trustworthy than typical cannabis marketing.

Institutional baseline from NIH and related sources

• NCCIH states the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea/vomiting, and appetite/weight-loss indications in HIV/AIDS. It notes only modest evidence for chronic pain and MS-related symptoms, with many other claimed uses still early-stage [1].
• NCCIH emphasizes FDA has not approved the cannabis plant itself for medical use, though purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns highlighted by NIH include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination/labeling inaccuracy, and THC-vape lung-injury concerns [1].
• NCCIH warns over-the-counter CBD products may differ from labels and CBD itself has been associated with decreased alertness, GI effects, liver adverse effects, and drug interactions [1].

For Kansas residents, these institutional positions carry particular weight. When state law is restrictive, understanding the federal scientific consensus helps inform personal decisions.

Cannabinoids

CBD

• Evidence profile: Strongest human evidence in our formula set, especially when studied as purified product [1]-[6].
• Best supported: Purified CBD has most credible human evidence in seizure disorders—clear major-example indication acknowledged by institutional and peer-reviewed literature [1][2].
• Anxiety research: 2024 systematic review/meta-analysis of 316 participants across eight articles reported significant anxiolytic signal, but authors stressed clinical sample remains limited and more trials needed [3].
• Pain research: 2024 systematic review of clinical/preclinical CBD monotherapy concluded pain literature is promising but heterogeneous, with trial quality/consistency limiting confidence [4].
• Sleep research: 2023 insomnia review found literature remains methodologically weak, with many studies relying on nonvalidated subjective measures [5].
• Safety/interaction concerns: 2023 systematic review/meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, drug-drug interactions [1].
• Bottom line: CBD is most evidence-developed nonintoxicating cannabinoid here, but strong evidence is concentrated in few specific indications rather than broad wellness claims [1]-[6].

CBG

• Evidence profile: Mostly review-level and preclinical; human evidence sparse [7][8].
• Pharmacology: CBG is biosynthetic precursor to several major cannabinoids, appears pharmacologically distinct from THC and CBD. Review literature describes interactions spanning cannabinoid receptors plus alpha-2 adrenoceptors and 5-HT1A-related signaling—mechanistically interesting but not clinically established [7].
• Potential research areas: Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, antibacterial activity, but primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions [7][8].
• Caution: 2021 pharmacology review notes CBG is already being sold commercially while evidence base remains thin, meaning claims frequently outrun science [7].
• Bottom line: CBG is serious research topic, but presently should be described as promising minor cannabinoid with limited clinical validation rather than proven therapeutic [7][8].

Delta-8 THC

• Evidence profile: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11].
• Comparative pharmacology: 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic/pharmacodynamic behavior. Delta-8 is partial CB1 agonist with cannabimimetic activity in animals and humans, appears less potent than delta-9 THC, likely in part due to weaker CB1 affinity [9].
• Public-health literature: 2023 scoping review found delta-8 evidence base dominated by animal studies, product chemistry, use reports, public-health concerns rather than strong modern human trials. Noted reports of adverse consequences, emphasized regulatory and product-quality concerns [10].
• Manufacturing context: Recent chemistry/pharmacology review reinforces commercial delta-8 interest tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product byproduct and lab-testing questions matter [11].
• Bottom line: Delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11].

THCa

• Evidence profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence [12].
• What it is: THCa is acidic precursor of THC and may represent large share of THC-related content in raw plant material. Key formulation issue: THCa decarboxylates into THC during heating and can change over time during storage/processing [12].
• Psychoactivity: Major review stresses THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays in acidic form and is not substantially decarboxylated [12].
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities, but not equivalent to established human outcomes [12].
• Bottom line: THCa best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, storage. Any claim about THCa needs to account for possible conversion into THC [12].

Delta-9 THC

• Evidence profile: Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15].
• Institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea/vomiting, appetite/weight loss in HIV/AIDS, some multiple-sclerosis- and pain-related outcomes, while stressing many other uses remain uncertain or early-stage [1].
• Pain evidence: 2022 systematic review of cannabis-based products for chronic pain found products with high THC content or comparable THC:CBD ratios may provide short-term pain benefit, but also increased dizziness, sedation, nausea, treatment discontinuation due to adverse events [13].
• Pharmacokinetics/onset: Classic literature remains useful: inhaled THC produces effects within seconds to minutes, peaks ~15-30 minutes, tapers over few hours; oral THC has later onset, later peak, longer duration, which matters for both benefit and overconsumption risk [14].
• Mental-health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression in nontherapeutic settings [15].
• Broader safety: Institutional/review literature describes anxiety/panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, vape-related lung-injury concerns in THC-containing products [1][14][15].
• Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings, but also carries clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15].

CBN

• Evidence profile: Weak human evidence; marketing has clearly moved ahead of data [12][16][17].
• What marketed for: Sleep and sedation. Reputation widespread, but clinical support far thinner than market suggests [16][17].
• Best direct review for sleep claim: 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims [16].
• Broader sleep literature: 2024 updated review on cannabis and sleep concluded overall cannabinoid sleep research still does not match scale of real-world use, need for better-designed, adequately powered trials remains substantial [17].
• Chemical context: Downstream cannabinoid degradation pathways matter; review literature on THCa notes THC can further degrade toward CBN under certain conditions, helping explain why CBN often discussed in aging/oxidized cannabis chemistry contexts [12].
• Bottom line: CBN is one of clearest examples where cultural reputation is stronger than current clinical evidence base [16][17].

CBC

• Evidence profile: Emerging, intriguing, still overwhelmingly preclinical or review-based [18][19].
• Pharmacology/therapeutic interest: 2024 focused review on CBC argues it has distinct pharmacodynamics, pharmacokinetics, receptor behavior relative to better-known cannabinoids, highlights antinociceptive, antibacterial, anti-seizure areas as especially interesting research targets [18].
• What older literature shows: Review literature summarizing CBC in animal/in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological or antiproliferative relevance, but signals not yet strong evidence for patient-facing claims [19].
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products already being sold despite little evidence establishing clinical efficacy or safety [18].
• Bottom line: CBC belongs in category of scientifically credible minor cannabinoids that deserve more research, not in category of already-validated clinical actives [18][19].

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

• Evidence profile: Largely review and preclinical, with useful safety literature [20]-[22].
• Potential activity: 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities, but overwhelming share of claims comes from nonhuman or non-cannabis literature [21].
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature [22].
• Bottom line: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22].

Myrcene

• Evidence profile: Mostly preclinical, very limited human evidence [20][23].
• Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties and discusses possible mechanisms, but explicitly states human studies lacking [23].
• Interpretation caution: Myrcene often invoked in consumer language as if it were proven sedating terpene that explains couch-lock or sleep effects. That is stronger claim than human evidence currently supports [20][23].
• Bottom line: Myrcene is plausible bioactive terpene, but compound-specific clinical claims about mood, pain, sedation remain far ahead of definitive human proof [23].

Caryophyllene

• Evidence profile: Among most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].
• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, unusual and especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24].
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions repeatedly discussed, but human clinical confirmation remains limited [24].
• Bottom line: Beta-caryophyllene is arguably strongest candidate for terpene with cannabinoid-system significance, but still should not be described as clinically proven for outcomes commonly attributed [24].

Pinene

• Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25].
• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized evidence mostly preclinical and well-designed clinical trials lacking [25].
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].
• Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool

• Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
• Research summary: Linalool repeatedly discussed in relation to stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological/psychiatric contexts, while still emphasizing lack of robust human trials [25].
• Additional literature: Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but remains translational rather than definitive clinical story [26].
• Safety note: As with limonene, oxidized linalool hydroperoxides recognized allergens in dermatitis literature [22].
• Bottom line: Linalool is scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene

• Evidence profile: Translationally interesting, but still early [20][27].
• Scoping-review findings: 2024 scoping review analyzed 340 articles, found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].
• Interpretation caution: Findings valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, mood outcomes [27].
• Bottom line: Humulene is one of more interesting terpene research targets in this list, but remains far from clinically settled [27].

Terpinolene

• Evidence profile: One of least clinically characterized terpenes in this file [20][28].
• Systematic-review findings: 2021 terpinolene review screened 2,449 records, included 57 studies, concluded terpinolene has range of reported biological effects but evidence base still dominated by in silico, in vitro, and animal studies rather than human trials [28].
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not established compound-specific clinical effects [20].
• Bottom line: Terpinolene is biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28].

Research limits and interpretation

• Evidence base is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. Common error in cannabis writing is letting evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14].
• For THCa particularly, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].

Common overstatements to avoid

• Overstatement: CBN is clinically proven sleep cannabinoid.
  More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].
• Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].
• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12].
• Overstatement: Delta-8 THC is safe because it is hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical takeaways for the formulas in this document

• Most evidence-developed actives in these formulas are CBD and delta-9 THC.
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety/efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted same way in raw, gently handled, and heated formats.
• CBG, CBN, CBC are scientifically credible but clinically immature compared with CBD and THC.
• Listed terpenes likely highly relevant to aroma, flavor, potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

References

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30 mL bottle with graduated dropper (0.1 mL increments)
• Active cannabinoids per mL: 553 mg
• Carrier: Organic MCT oil
• Price: $129.99
• Shipping to Butler County, Kansas: 2-3 business days via USPS Priority Mail

Usage guidance for Butler County:

• Raw (non-decarboxylated): Start with 0.25 mL (138 mg cannabinoids) for daytime anti-inflammatory support without impairment
• Decarboxylated: Heat at 260°F for 45-60 minutes, then start with 0.1 mL (55 mg cannabinoids) for evening use
• At 0.5 mL raw: 276 mg total cannabinoids, including 75 mg CBD, 50 mg CBG, 100 mg delta-8 THC, 25 mg THCa, 1.5 mg delta-9 THC, 12.5 mg CBN, 12.5 mg CBC
• At 1.0 mL decarbed: 553 mg total cannabinoids, including ~150 mg CBD, ~100 mg CBG, ~200 mg delta-8 THC, ~44 mg delta-9 THC (from THCa conversion), 3 mg delta-9 THC, ~25 mg CBN, ~25 mg CBC

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge (510-thread)
• Total cannabinoids: 900+ mg
• Compatibility: Works with any standard 510-thread battery available in Butler County vape shops or online
• Price: $49.99
• Shipping to Butler County, Kansas: 2-3 business days

Usage guidance for Butler County:

• 2-3 puffs delivers ~10-15 mg total cannabinoids with 1-2 minute onset
• Each puff auto-decarboxylates THCa to delta-9 THC at vaporization temperature (400-450°F)
• Ideal for breakthrough pain, acute anxiety, or nausea episodes
• Compact and discreet for use during hunting trips, fishing at El Dorado Lake, or community events

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene (citrus-bright)—common in citrus peels, may support mood
• Myrcene—found in mangoes, hops; traditionally associated with relaxation
• Caryophyllene (β-caryophyllene – pepper/spice)—unique as dietary cannabinoid, binds CB2 receptors
• Pinene (forest-fresh)—aromatic in pine forests around Kansas, may support alertness
• Linalool (floral, lavender)—common in lavender, associated with calm
• Humulene (earthy, woody)—found in hops, may have anti-inflammatory properties
• Terpinolene (piney, fruity, sparkling)—complex aroma found in some cannabis cultivars

This seven-terpene profile is identical in both products, providing consistent aromatic and potential entourage benefits whether you choose sublingual or vape format.

FINAL THOUGHTS FOR BUTLER COUNTY

We know Kansas isn’t California or Colorado. We know Butler County values hard work, honesty, community, and looking your neighbor in the eye. We know the opioid crisis has hit rural Kansas harder than most places, and that many of you have lost people you love to pharmaceuticals that were supposed to help. We know you’re skeptical of out-of-state companies promising miracles.

That’s why we published this entire document—every reference, every formula, every piece of evidence we rely on. That’s why Colin’s personal story of Bentley, of benzo withdrawal, of cannabis conviction, is here. That’s why the ABC13 media record spanning four years is documented in full. That’s why we’ve told you exactly what the science says and, just as importantly, what it doesn’t say.

For Butler County residents dealing with chronic pain that makes walking the land painful, with cancer that the treatments at Susan B. Allen or Wesley Medical Center are struggling to manage, with PTSD that the VA system hasn’t adequately addressed, with sleepless nights and anxious days—we’re not here to tell you RSO is a miracle. We’re here to tell you it’s a tool. A well-researched, carefully formulated, legally accessible tool that you can control. A tool that might be right for you, or might not—but you deserve information honest enough to make that decision yourself.

The formulas are published. The research is cited. The legal framework is explained. The risks are laid bare. The benefits are contextualized to actual evidence, not marketing fantasy.

If you’re ready to explore whether OilWell’s RSO might fit into your health journey in Butler County, Kansas, we’re here. No medical card needed. Just age 21+. We’ll ship it to your door with full documentation, third-party lab testing, and the same commitment to quality that kept Bentley alive for ten years and that helped Colin quit benzos cold turkey.

Order today at oilwellcbd.com or call us at (832) 416-2816. Our customer service team can answer your questions, help you understand the legal landscape in Kansas, and guide you toward the product format that makes sense for your life—whether that’s sublingual oil for sustained relief or vape for breakthrough moments.

Business Hours:
Monday-Thursday: 10:00 AM – 7:00 PM
Friday-Saturday: 10:00 AM – 10:00 PM
Sunday: 10:00 AM – 4:00 PM

Contact:
Phone: (832) 416-2816
Email: [email protected]
Website: https://oilwellcbd.com/
Instagram: @oilwellcbd

Please note: These products are not intended to diagnose, treat, cure, or prevent any disease. The FDA has not evaluated these statements. Individual results may vary. Consult your healthcare provider before use, especially if you are pregnant, nursing, have a medical condition, or take medications. Do not operate vehicles or machinery under the influence of psychoactive cannabinoids. You must be 21 years of age or older to purchase. Buyer assumes all responsibility for compliance with local laws. OilWell Cannabis assumes no legal liability for customer use or decarboxylation decisions. Void where prohibited by law.

For Butler County, Kansas residents specifically: Kansas law regarding hemp-derived products is subject to interpretation. While our products meet federal Farm Bill standards, Kansas state law enforcement may have different interpretations. We recommend consulting with a local attorney if you have concerns about legality. Our products ship with complete Certificates of Analysis documenting compliance with federal <0.3% delta-9 THC requirements.

Thank you for taking the time to read this comprehensive guide. We respect the intelligence and independence of Butler County residents, and we hope this information helps you make the best decision for your health.